Literature DB >> 8576551

The neuronal ceroid-lipofuscinoses.

H H Goebel1.   

Abstract

The neuronal ceroid-lipofuscinoses, a group of progressive neurodegenerative diseases in children and in adults, have now been recognized for some 90 years, and the childhood forms represent one of the largest groups of progressive neurodegenerative diseases in children. Apart from a core group of major clinical forms-the infantile, the late-infantile, the juvenile, and the adult forms--numerous atypical patients afflicted with neuronal ceroid-lipofuscinosis have now been identified, constituting 10% to 20% of all patients with neuronal ceroid-lipofuscinosis. These "atypical" patients have, over the past 10 years, prompted the suggestion of 15 atypical variants or minor syndromes, many of them displaying the lipopigments of classic curvilinear and fingerprint ultrastructure, but others displaying granular osmiophilic deposits. The former lipopigments contain the subunit C of the mitochondrial adenosine triphosphate synthase, but lipopigments of the granular osmiophilic deposits including the classic infantile type Santavuori-Haltia, apparently do not, the latter type exhibiting sphingolipid activator proteins. The nosologic significance of both the subunit C of the adenosine triphosphate synthase and the sphingolipid activator proteins, although they make up a considerable amount of the crude auto-fluorescent lipopigments in neuronal ceroid-lipofuscinosis, is still unclear. In spite of numerous pathogenetic principles invoked, such as a defect in lipid peroxidation, abnormalities of dolichols and dolichol phosphates, and defects in protease inhibitors, precise pathogenesis and etiology of the neuronal ceroid-lipofuscinoses remain elusive. Recent promising molecular genetic studies have, however, revealed the gene for infantile neuronal ceroid-lipofuscinosis, CLN1, on chromosome 1p32; the gene for juvenile neuronal ceroid-lipofuscinosis, CLN3, on chromosome 16p12.1-11.2; and the gene for a Finnish variant of late-infantile neuronal ceroid-lipofuscinosis, CLN5, on chromosome 13q31-32. The genes for classic late-infantile neuronal ceroid-lipofuscinosis, CLN2, and for adult neuronal ceroid-lipofuscinosis, CLN4, have not been located, the former having been excluded from chromosomes 1 and 16. However, the gene products of the normal allelic forms have not yet been identified. A considerable number of sporadic animal models is now available, largely equivalent to the juvenile and infantile forms of neuronal ceroid-lipofuscinosis, with those of the English setter and the South Hampshire sheep evaluated best. Recently, several mouse models have been added to this list of autosomal-recessive models, again the one most thoroughly studied being the motor-neuron disease mouse. Progress has also been made in the prenatal diagnosis of neuronal ceroid-lipofuscinosis: now the infantile, late-infantile, and juvenile forms can be recognized prenatally by a combined genetic and electron microscopic approach.

Entities:  

Mesh:

Year:  1995        PMID: 8576551     DOI: 10.1177/088307389501000602

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  29 in total

1.  Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Serena Ramji; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

Review 2.  Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.

Authors:  Sara E Mole; Ruth E Williams; Hans H Goebel
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

3.  Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Gábor Szénási; Péter Kiricsi; Eva Szabó; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2010-10-29       Impact factor: 5.250

4.  Phenotypic reversal of the btn1 defects in yeast by chloroquine: a yeast model for Batten disease.

Authors:  D A Pearce; C J Carr; B Das; F Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  The yeast model for batten disease: mutations in BTN1, BTN2, and HSP30 alter pH homeostasis.

Authors:  S Chattopadhyay; N E Muzaffar; F Sherman; D A Pearce
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

6.  Seizure susceptibility, phenotype, and resultant growth delay in the nclf and mnd mouse models of neuronal ceroid lipofuscinoses.

Authors:  Elizabeth Kriscenski-Perry; Attila D Kovács; David A Pearce
Journal:  J Child Neurol       Date:  2013-07-09       Impact factor: 1.987

7.  Nitric oxide signaling is disrupted in the yeast model for Batten disease.

Authors:  Nuno S Osório; Agostinho Carvalho; Agostinho J Almeida; Sérgio Padilla-Lopez; Cecília Leão; João Laranjinha; Paula Ludovico; David A Pearce; Fernando Rodrigues
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

8.  pdf1, a palmitoyl protein thioesterase 1 Ortholog in Schizosaccharomyces pombe: a yeast model of infantile Batten disease.

Authors:  Steve K Cho; Sandra L Hofmann
Journal:  Eukaryot Cell       Date:  2004-04

9.  A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease.

Authors:  Yoojin Kim; Denia Ramirez-Montealegre; David A Pearce
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

10.  Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease.

Authors:  Catherine Kielar; Thomas M Wishart; Alice Palmer; Sybille Dihanich; Andrew M Wong; Shannon L Macauley; Chun-Hung Chan; Mark S Sands; David A Pearce; Jonathan D Cooper; Thomas H Gillingwater
Journal:  Hum Mol Genet       Date:  2009-07-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.